BALZERS, Liechtenstein & JINJU, South Korea–(BUSINESS WIRE)–#Artilysin–South Korean KOSDAQ listed AMICOGEN Inc. will become the latest shareholder in Lysando AG. The transaction includes an acquisition of shares, a cash contribution to Lysando and a share package to Lysando into AMICOGEN.
The deal means an 8% participation of AMICOGEN into Lysando and 2.69% in shares for Lysando into AMICOGEN. The transactions were negotiated with a 300 Mio. Euro evaluation of Lysando.
Other shareholders of Lysando continue to be majority owner and Chairman of the Board Markus Graf Matuschka von Greiffenclau, Bangkok based SCG, and Lysando�s employees.
The companies have already a productive partnership in place, based on Lysando´s leading platform Artilysin®. It is a globally patented, sustainable and highly effective technology, fighting resistance of microbes, as an alternative to antibiotics and other antimicrobial treatments.
I am very happy and proud to welcome AMICOGEN as a new shareholder of Lysando. AMICOGEN being such a strong and successfully operating CDMO, Asian markets, in particular China and South Korea, can now be approached faster and with the highest level of sufficiency. Our microbiome-friendly Artilysin®-platform has incredible potential for the benefit of humanity, pets, farmed animals and the environment which can be implemented even better now, says Lysando´s chairman Markus Graf Matuschka von Greiffenclau.
Global spreading resistance and our increasing knowledge about the importance of a balanced microbiome require innovation and a new way of thinking. We had been impressed with the potential of Artilysin® from the very beginning. I am looking very much forward pushing our partnership to the next level, intensifying our company´s interfaces and therefore merge know-how to even further drive the success and growth of the Artilysin®-platform., says Yong Chul Shin, CEO of AMICOGEN.
Amicogen Inc.
Amicogen Inc., 092040:KOSDAQ develops, produces and markets specialty enzymes and functional food ingredients. The company offers special biocatalysts, enzyme-based new functional materials, health foods, and consumer products.
Lysando AG
Lysando AG is market-leader for antimicrobial proteins, so-called Artilysin®s.
Artilysin®s are a new class of molecules showing a high resistance stability and are microbiome- and environmentally-friendly. Artilysin®s can be employed in all fields, bacteria present a problem like Medical Devices, Human Pharmaceutics, Animal Health and Consumer Care.
Contacts
Company
Lysando AG
Verena Schossmann
+41(0)79-211-83-42
verena.schossmann@lysando.com
Media
Three Winters GmbH
Prof. Wolfram Winter
+49(0)171-2345-515
wolfram@3winters.de
Strengthens end-to-end RCM offering to healthcare providers Expands service capabilities to US physicians’ practices, and…
SINGAPORE - Media OutReach Newswire - 3 May 2024 - UPCX (UPC), a developer of…
DUBLIN--(BUSINESS WIRE)--The "China Biological Reagents Market (Molecular Biology Reagents, Proteins and Cell Reagents): Insights &…
DALLAS & NEW YORK & LONDON & TOKYO--(BUSINESS WIRE)--Lone Star Funds (“Lone Star”) today announced…
TAIPEI, Taiwan--(BUSINESS WIRE)--#AI--NVIDIA’s next-gen Blackwell platform, which includes B-series GPUs and integrates NVIDIA’s own Grace…
DUBLIN--(BUSINESS WIRE)--The "Asia-Pacific Solid-State Battery Market: Focus on Electrolyte Type, Battery Type, Capacity, Application, and…